ERBB2 and ductal breast carcinoma in situ: Total lesion size > 2 cm (p = 0.046), axillary LN metastasis (p < 0.001), comedo necrosis (p = 0.005), NG3 (p = 0.001), HER2-positivity (p = 0.018), and adjuvant chemotherapy (p = 0.043) were significantly higher in the DCIS-Mi group than in the DCIS group.